ArticleClinical and experimental medicine2024
Correction to: SRRM2 may be a potential biomarker and immunotherapy target for multiple myeloma: a real-world study based on flow cytometry detection.
Jinjing Guo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.